Ethris is a global leader in delivering messenger ribonucleic acid (mRNA) therapeutics directly to the respiratory system, including administering by inhalation
Indian pharma major Cipla to collaborate with German firm Ethris for developing mRNA-based therapeutics. Cipla’s UK arm signed a €15 million agreement with Ethris regarding this.
Ethris is a global leader in delivering messenger ribonucleic acid (mRNA) therapeutics directly to the respiratory system, including administering by inhalation.
This long-term strategic collaboration is aimed at fast-tracking Cipla’s participation in the mRNA space as well as to make Ethris’ cutting-edge solutions accessible to developing nations, Cipla said in a press release.
“This collaboration accelerates our innovation journey and enables us to provide access to cutting-edge healthcare solutions to our patients. We expect mRNA-based therapies to be one of the key innovation levers for Cipla,” said Umang Vohra, MD & Global CEO of Cipla.
The partnership will also help Cipla become a global leader in the respiratory care segment. Cipla expects to finish the transaction within 60 days.
“This inhaled mRNA technology is a paradigm shift in the delivery mechanism and this partnership reinforces Cipla’s strength in respiratory therapy in line with our aspiration of attaining global lung leadership,” Vohra added.
Cipla’s biggest markets lie in India and the US—two countries in which the pharma major has reported double digit growth in revenue. In the previous quarter, Cipla reported 6 per cent increase in consolidated revenue and 12 per cent growth in net profit.
For the quarter-ended September, Cipla’s consolidated revenue stood at Rs 5829 crore and net profit was at Rs 797 crore.